-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics publishes corporate overview outlining oncology pipeline and development plans

PUBT·04/28/2026 00:57:06
Listen to the news
Kazia Therapeutics publishes corporate overview outlining oncology pipeline and development plans
  • Kazia Therapeutics outlined strategy to broaden oncology pipeline beyond lead brain-penetrant PI3K/mTOR inhibitor paxalisib into immuno-oncology protein degradation and epigenetic modulation.
  • Paxalisib has been evaluated in more than 550 adult and pediatric patients across Phase 1-3 trials and expanded access programs.
  • Company highlighted January 2026 clinical updates in metastatic TNBC, including one complete metabolic response under expanded access and two partial responses in ongoing Phase 1b study.
  • Kazia reported cash and cash equivalents of about USD 46 million, with expected runway into 2029, excluding additional or expanded trials.
  • Pipeline buildout includes NDL2 intracellular PD-L1 protein degrader and MSETC SETDB1 inhibitor, with IND-enabling studies slated to start in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.